Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.86 Analyst target: $15.50 Upside: 1700.23%
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease. The company is headquartered in San Carlos, California.
See the full interactive analysis & chart →Informational only — not investment advice.